Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ValiRx plc (VAL.L)
Hatfield, GB
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -30.36% | -40.91% | -43.48% | -41.79% | -64.55% | -97.89% | -99.05% | -97.98% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-37.0% Q4'25: +226.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+62.8% ★ Q4'25: +80.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-6,800.6% Q4'25: -1,654.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-7,688.4% Q4'25: -2,832.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-150.2% Q4'25: -210.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+213.8% Q4'25: +616.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
82.6K
est: 300.0K (-72.5%)
|
—
est: 15.10M (-100.0%)
|
49.8K
est: 49.8K (+0.0%)
|
| EBITDA |
-2.14M
est: 60.0K (-3,661.8%)
|
-5.31M
est: 3.02M (-275.8%)
|
-1.86M
est: 10.0K (-18,807.9%)
|
| EBIT |
-2.24M
est: 60.0K (-3,830.1%)
|
-5.41M
est: 3.02M (-279.2%)
|
-2.13M
est: 10.0K (-21,490.2%)
|
| Net Income |
-2.12M
est: -16.47M (+87.1%)
|
-4.75M
est: 164.72M (-102.9%)
|
-1.92M
|
| SGA |
1.69M
est: 12.99M (-87.0%)
|
1.79M
est: 653.79M (-99.7%)
|
1.98M
est: 2.16M (-8.3%)
|
| EPS |
-8.33
est: -0.13 (-6,564.0%)
|
-10.28
est: 1.25 (-922.4%)
|
-0.01
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab Fundamental Emerging Markets Large Company Index ETF FNDE | 0.55% | 51.78M | 0.39% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.17% | 20.85M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Eccleston | Chief Executive Officer, Director, Member of Scientific & Commercial Advisory Board | 83.4K | — |
| James Gerry Desler | Chief Financial Officer, Company Secretary & Executive Director | 66.5K | male |
| Andrew Carnegie | Head of Strategic Commercial Development | — | — |
| Kumar Nawani | Head of Operations | — | male |
| Mark Treharne | Corporate Development Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VAL.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
